THE CAMPTOTHECINS
FROM DISCOVERY
TO THE PATIENT

Edited by Panayotis Pantazis, Beppino C. Giovanella,
and Mace L. Rothenberg

The New York Academy of Sciences
New York, New York
1996
CONTENTS

Introduction and Overview. By JOHN S. STEHLIN .............................. ix

Part I. Synthesis, Chemistry, and Activity of Camptothecins

Camptothecin: Discovery to Clinic. By MONROE E. WALL AND MANSUKH
C. WANI ....................................................... 1

Synthesis of CPT-11 (Irinotecan Hydrochloride Trihydrate).
By S. SAWADA, T. YOKOKURA, AND T. MIYASAKA ............................. 13

Chemistry of the Camptothecins in the Bloodstream: Drug Stabilization
and Optimization of Activity. By THOMAS G. BURKE ......................... 29

Part II. Interactions of Camptothecins with Cellular Components
and Other Agents

Using Yeast to Understand Drugs that Target Topoisomerases.
By JOHN L. NITISS, ANGELA ROSE, KARIN C. SYKES, JAMES HARRIS,
AND JUNFANG ZHOU ........................................... 32

Mechanism of Action of Camptothecin. By LEROY F. LIU, PU DUANN,
CHING-TAI LIN, PETER D’ARPA, AND JIAI WU ................................. 44

The Effect of Camptothecin on Topoisomerase I Catalysis.
By KENT CHRISTIANSEN AND OLE WESTERGAARD .......................... 50

Part III. Induction of Apoptosis and Development of Resistance
to Camptothecins

Cellular Resistance to Camptothecins. By YVES POMMIER, MALINI
GUPTA, MONICA VALENTI, AND WILBERTO NIEVES-NEIRA .................. 60

Camptothecin Resistance Related to Drug-induced Down-Regulation of
Topoisomerase I and to Steps Occurring after the Formation of
Protein-linked DNA Breaks. By JOHN R. MURREN, DAVID R.
BEIDLER, AND YUNG CHI CHENG .................................. 74

The Cell Cycle Effects of Camptothecin. By ZBIGNIEW DARZYNKIEWICZ,
SILVIA BRUNO, GIACINTA DEL BINO, AND FRANK TRAGANOS ............. 93

Induction of Apoptosis by Camptothecin and Topotecan. By FRANK
TRAGANOS, KAREN SEITER, ERIC FELDMAN, H. DOROTA HALICKA,
AND ZBIGNIEW DARZYNKIEWICZ ..................................... 101

This volume is the result of a conference entitled The Camptothecins: From Discovery to the
Patient, which was held by the New York Academy of Sciences in Bethesda, Maryland on February
7 - 10, 1996.
Identification of Topoisomerase I Mutations Affecting Both DNA Cleavage and Interaction with Camptothecin. By XI-GUANG LI, PAUL HALUSKA, JR., YAW-HUEI HSING, AJIT BHARTI, DONALD W. KUFE, AND ERIC H. RUBIN

Factors Affecting Topotecan Sensitivity in Human Leukemia Samples. By SCOTT H. KAUFMANN, STEVEN D. GORE, LOUIS LETENDRE, PHYLLIS A. SVINGEN, TIMOTHY KOTTKER, CHRISTOPHER A. BUCKWALTER, RICHARD J. JONES, LOUISE B. GROCHOW, PHILIP J. BURKE, ROSS C. DONEhower, AND ERIC K. ROWINKSY

Induction of Apoptosis in Malignant and Camptothecin-resistant Human Cells. By DEVASIS CHATTERJEE, JAMES H. WYCHE, AND PANAYOTIS PANTAZIS

Part IV. Pharmacology and Pharmacokinetics of Camptothecins
Pharmacokinetics of Camptothecins Administered Orally. By JOACHIM G. LIEHR, AHMED E. AHMED, AND BEPPINO C. GIOVANELLA
Clinical Pharmacology and Pharmacodynamics of Irinotecan: A Review. By GUY G. CHABOT
Preclinical Antitumor Activity and Pharmacokinetics of Irinotecan (CPT-11) in Tumor-bearing Mice. By MARIE-CHRISTINE BISSERY, PATRICIA VRIGNAUD, FRANCOIS LAVELLE, AND GUY G. CHABOT

Part V. Preclinical Investigations on Cytotoxicities and Antitumor Activities of Camptothecins
Protocols for the Treatment of Human Tumor Xenografts with Camptothecins. By B. C. GIOVANELLA, E. NATELSON, N. HARRIS, D. VARDEMAN, AND J. S. STEHLIN
Schedule-dependent Efficacy of Camptothecins in Models of Human Cancer. By PETER J. HOUGHTON, CLINTON F. STEWART, WILLIAM C. ZAMBONI, JOYCE THOMPSON, XIALONG LUO, MARY K. DANKS, AND JANET A. HOUGHTON
Topoisomerase I Inhibition by the Camptothecin Analog G1147211C: From the Laboratory to the Clinic. By JEFFREY M. BESTERMAN
Treatment of Central Nervous System Xenografts with Camptothecins. By HENRY S. FRIEDMAN AND PETER J. HOUGHTON

Part VI. Clinical Investigations
9-Aminocamptothecin and Beyond: Preclinical and Clinical Studies. By MILAN POTMESIL, SUSAN G. ARBUCK, CHRIS H. TAKIMOTO, LEONARD LIEBES, AND HOWARD HOCHSTER

Topoisomerase-I Inhibitors in the Management of Colon Cancer. By James K. V. Willson 256

Clinical Studies of Topotecan. By Colin Broom 264


Clinical Trials of Irinotecan Hydrochloride (CPT, Campto Injection, Topotecan Injection) in Japan. By Nagahiro Sajo 292

Poster Papers

Cytotoxic Efficacy with Combinations of Topoisomerase I and Topoisomerase II Inhibitors in Sensitive and Multidrug-resistant L1210 Mouse Leukemia Cells. By Dale Grabowski and Ram Ganapathi 306

Failure in DNA Elongation Predicts Sensitivity to Camptothecin in the Colon Cell Lines of the NCI Anticancer Drug Screen. By François Goldwasser, Tsunehiro Shimizu, and Yves Pommier 308


Pharmacokinetic and Pharmacodynamic Studies of 9-Aminocamptothecin in Vitro against Human Cancer Cells. By M. Li, M. J. Moore, B. Berry, and J. J. Thiessen 315

Implications for the Use of Topoisomerase I Inhibitors in Treatment of Patients with Systemic Sclerosis. By Lidia Rudnicka, Joanna Czuwara, Agnieszka Barusinska, Urszula Nowicka, Barbara Makieł, and Stefania Jablonska 318

Lowered Phosphorylation of Topoisomerase I Is a Direct Reason for Reduced Sensitivity of L5178Y-S Cells to Camptothecin. By Krzysztof Staron, Barbara Kowalska-Loth, and Irena Szumił 321

Financial assistance was received from:

**Major Funders**
- PHARMACIA & UPJOHN, INC.

**Supporters**
- JANSSEN PHARMACEUTICA
- NATIONAL CANCER INSTITUTE
- RHÔNE-POULENCE RORER
- SMITHKLINE BEECHAM PHARMACEUTICALS
- THE RGK FOUNDATION
- YAKULT HONSHA Co., LTD.

**Contributors**
- BOEHRINGER INGELHEIM KG
- DAIICHI PHARMACEUTICAL CORPORATION
- GENENTECH, INC.
- MARION MERRELL DOW, INC.
- RHÔNE-POULENCE RORER FOUNDATION
- THE STEHLIN FOUNDATION FOR CANCER RESEARCH

The New York Academy of Sciences believes it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the participants in the reported conferences are their own and not necessarily those of the Academy. The Academy has no intent to influence legislation by providing such forums.